24 oct 2017
CPhI Worldwide 2017
Xellia Pharmaceuticals ApS

Xellia Pharmaceuticals ApS

Exhibitor at CPhI Worldwide 2017 stand 91C80, Finished Dosage Formulations

About us

Xellia is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. Our anti-infective treatments combat serious bacterial and antibiotic resistant infections as well as certain fungal diseases.

Xellia is wholly owned by Novo Holdings A/S.

Production Sites: Five state-of-the-art manufacturing facilities located in; Denmark, Hungary, China and in the U.S.
Expertise: Xellia has over 100 years’ experience in the development, manufacture and supply of fermented and semi-synthetic Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). Xellia is the leading supplier of the important anti-infectives Vancomycin and Colistimethate Sodium (CMS).

Specs about this supplier

Sales markets Western Europe; Eastern Europe; Middle East; Asia; Australia; North America; Africa; Central/South America
Affiliated categories: Antibiotics |Generic APIs |Finished Dosage Forms More

Products featured at CPhI Worldwide 2017

Categories affiliated with Xellia Pharmaceuticals ApS

Xellia Pharmaceuticals ApS

Event information

CPhI Worldwide 2017

24 - 26 October 2017 Messe Frankfurt, Germany Visit us at stand 91C80